Intellia TherapeuticsNTLA
About: Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Employees: 598
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
91% more repeat investments, than reductions
Existing positions increased: 126 | Existing positions reduced: 66
43% more call options, than puts
Call options by funds: $16.5M | Put options by funds: $11.5M
31% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 49
5.71% more ownership
Funds ownership: 91.75% [Q3] → 97.45% (+5.71%) [Q4]
4% more funds holding
Funds holding: 280 [Q3] → 290 (+10) [Q4]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]
40% less capital invested
Capital invested by funds: $1.91B [Q3] → $1.16B (-$756M) [Q4]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Wolfe Research Andy Chen 53% 1-year accuracy 8 / 15 met price target | 137%upside $21 | Outperform Upgraded | 21 Apr 2025 |
HC Wainwright & Co. Mitchell Kapoor 31% 1-year accuracy 58 / 188 met price target | 238%upside $30 | Buy Initiated | 5 Mar 2025 |
Truist Securities Joon Lee 48% 1-year accuracy 20 / 42 met price target | 464%upside $50 | Buy Maintained | 4 Mar 2025 |
Barclays Gena Wang 14% 1-year accuracy 4 / 29 met price target | 193%upside $26 | Overweight Maintained | 28 Feb 2025 |
Citigroup David Lebowitz 37% 1-year accuracy 7 / 19 met price target | 58%upside $14 | Neutral Maintained | 28 Feb 2025 |
Financial journalist opinion
Based on 144 articles about NTLA published over the past 30 days









